Homepage > Company > Media > Blog > 2021 > OCULAR DISEASES SMALL MOLECULES LIBRARY

OCULAR DISEASES SMALL MOLECULES LIBRARY

ChemDiv presets a brand new OCULAR DISEASES SMALL MOLECULES LIBRARY (13,000 compounds, 7 targets, 4 diseases)

For design of screening library we use emerging Targets: retinol binding protein 4 (RBP4), factor D inhibition as alternative complement pathway and VEGF pathway.

This library covers several ocular diseases: Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Cataract, Glaucoma.

Chemical compounds can be delivered as dry powders in 96 plates format or DMSO solutions frozen in 96 and /or 384 plates format. Cherry picking is available.

Please contact us to discuss delivery options of screening library, selection details, format requirements and options, quotation request at chemdiv@chemdiv.com.

More details ⬇️

https://store.chemdiv.com/catalog/therapeutical_areas/ocular_diseases_small_molecules_library/

Read also

CHEMDIV IS NOW A DISCOVERY PARTNER WITH GWYNANT THERAPEUTICS AND CELYN THERAPEUTICS

ChemDiv has been selected as a discovery partner with Gwynant Therapeutics and Celyn Therapeutics and starts to work on novel small molecules for oncology targets.

Our covalent compound library is now available in a ready-to-dock format for BioSolveIT

ChemDiv,Inc.

Science & Nature reviews, August 2021 (2)

These are ChemDiv's reviews on Nature and Science Journal articles.

Science & Nature reviews, August 2021 (1)

Here are ChemDiv's reviews on Nature and Science Journal articles.